Russia's Third COVID-19 Vaccine is for Adolescents
The Deputy Director-General of the Gamaleya Research Institute of Epidemiology and Microbiology Denis Logunov stated at a press conference in Moscow, Russia, on November 24, 2021, "The use of the Sputnik M vaccine by people twelve to 17 years was authorized today.'
Sputnik M is a recombinant human adenoviral-based, two-part, reduced dosage COVID-19 vaccine created for adolescents. This vaccine could be available in late 2021.
Gamaleya developed the original two-dose Sputnik V vaccine that was registered in Russia on August 11, 2020, and is currently available in 71 countries.
Then the single-dose Sputnik Light vaccine was registered on May 6, 2021.
The World Health Organization and the U.S. FDA have yet to authorize any Sputnik vaccine.
But the European Medicines Agency began its rolling-review process in March 2021.
Furthermore, the Sputnik vaccine team posted on Twitter 'Countering New Cases Surge in Europe' regarding the surge of COVID-19 related fatalities in Europe and Russia.